Full Press Release Details
December 2019 Exhibit 99.1
Forward Looking Statements Certain of
the statements made in these slides and the accompanying oral presentation are forward looking, including those relating to Neoleukin's business, strategy, future operations, advancement of its product candidates and product pipeline, clinical
development of its product candidates, including expectations regarding timing of regulatory submissions and initiation of clinical trials, regulatory requirements for initiation of clinical trials and registration of product candidates, the
sufficiency of its cash resources and other statements containing the words "anticipate," "believe," "expect," "may," "plan," "project," "potential,"
"will," "would," "could," "continue," and similar expressions. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those
anticipated, including, but not limited to, risks and uncertainties related to: whether results of early clinical trials or preclinical studies will be indicative of the results of future trials, the adequacy of any clinical models, uncertainties
associated with regulatory review of clinical trials; our ability to identify or acquire additional clinical candidates, our ability to obtain and maintain regulatory approval for any product candidates and the potential safety, efficacy or clinical
utility of or any product candidates, and other factors discussed in the "Risk Factors" section of the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2019 and Current Report on Form 8-K filed on
November 13, 2019, each as filed with the Securities and Exchange Commission. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. More information about the risks and
uncertainties faced by the Company is contained in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, and subsequent reports, filed with the Securities and Exchange Commission. The Company disclaims any intention or
Neoleukin Therapeutics (NASDAQ: NLTX)
was founded in 2018 and merged with Aquinox Pharmaceuticals in August 2019 Platform technology utilizes computational methods for de novo protein design of NeoleukinTM cytokine mimetics Lead program: NL-201, a highly potent, non-alpha, agonist of
IL-2 and IL-15 receptors for cancer immunotherapy Headquartered in Seattle; 36 employees Neoleukin Therapeutics Leader in de novo protein therapeutics for cancer, inflammation, and autoimmune diseases 2019 Neoleukin Therapeutics. All Rights
Reserved: Do not distribute or reproduce
Carl Walkey, Ph.D. VP, Corporate
Development Previous: Postdoctoral Fellow, IPD, UW Daniel-Adriano Silva, Ph.D. VP, Head of Research Previous: Translational Investigator, IPD, UW Umut Ulge, M.D., Ph.D. VP, Translational Medicine Previous: Postdoctoral Fellow, UW Jonathan Drachman,
VP, People Previous: Seattle Genetics, Microsoft Leslie Aberman, J.D. VP, IP & Legal Affairs Previous: IDRI, Seattle Genetics Leadership Team
Board of Directors Lewis T. Williams,
M.D., Ph.D. Director CEO Walking Fish Therapeutics Previous: CEO, FivePrime Therapeutics Todd Simpson Director CFO Seattle Genetics Cantey Boyd Director Managing Director, Baker Brothers Advisors Sarah Noonberg, M.D. Director Previous: CMO, Nohla
Functional De Novo Proteins: Better
Immunotherapies by Design Computational algorithms invented by Daniel-Adriano Silva at UW IPD NL-201: IL-2/IL-15 cytokine mimetic (Neoleukin ) for cancer immunotherapy Discovery published in Nature January 2019 Company formed to advance
Neoleukin Therapeutics: Pioneers in De
Novo Protein Design Technology originated at University of Washington's Institute for Protein Design, led by David Baker, PhD Scientific founders are world leaders in de novo protein design Exclusive license obtained for commercialization of
The Good and Bad of Interleukin-2
(IL-2) Immunotherapy IL-2 one of the few immunology drugs proven to work as single-agent Stimulates T cells to fight cancer rhIL-2 (Proleukin ) approved for RCC and melanoma Durable remissions in 5-8% of patients Vascular leak syndrome,
Off-Target Cells Toxicity & Less
Building a NeoleukinTM Cytokine
Mimetic in 4 Steps Step 1: Develop an accurate structural model of the target Step 2: Identify regions of intermolecular contact Step 3: Design an idealized topology Step 4: Identify optimal amino acid sequence 2019 Neoleukin Therapeutics.
Crystal Structure Shows Neo-2/15
Binding IL-2R / as Predicted hIL-2 h (CD25) h h Co-crystal structure of IL-2 Co-crystal structure Neoleukin-2/15 (14% linear sequence identity) Neo-2/15 Source: Silva et al. Nature, 565, 186-191 (2019) 2019
Neo-2/15 Binds IL-2R /
Neo-2/15 Is More Active than IL-2 in
Neo-2/15 Demonstrates Superior
Neo-2/15 Enhances CD8:Treg Ratio
Neo-2/15 Does Not Elicit Detectable
NL-201 Improves on Nature: Designed
to retain benefits of IL-2 without drawbacks No binding to alpha chain No bias toward endothelial cells or T-regulatory cells Potent IL-2 activation Potent IL-15 activation Hyper stable Higher affinity binding than natural protein Dual immune
IL-2/IL-15 Competitive Landscape
Other IL-2/IL-15 immunotherapies in development are modified versions of native IL-2 or IL-15 IL-2 modifications often result in less potent, less stable molecules, with some residual binding to the alpha subunit We believe that NL-201 is the only
NeoleukinTM Cytokine Mimetics are
Hyperstable and Easily Modified Can use with targeting domain to improve biodistribution Able to adjust half-life or tune affinity Can be conditionally activated in the tumor microenvironment Able to withstand extreme conditions Can be modified to
Financial Highlights & Upcoming
operations through 2021 Event Timeline Present Preclinical and Scientific Data 1H 2020 Submit IND for NL-201 By end of 2020
Improving on nature. Designing for